Table 1.
Distribution of clinicopathological features and immunohistochemistry-based breast cancer subtypes (n = 912).
| Median age, years, median (range) | 47 (23–85) | |
|---|---|---|
| Clinicopathological features | Number | Percentage (%) |
| Tumor size | ||
| T0 | 19 | 2.0 |
| T1 | 143 | 15.6 |
| T2 | 483 | 52.9 |
| T3 | 126 | 13.8 |
| T4 | 86 | 9.4 |
| Tx | 55 | 6.0 |
| Nodal status | ||
| N0 | 283 | 28.8 |
| N1 | 299 | 32.7 |
| N2 | 176 | 19.2 |
| N3 | 102 | 11.1 |
| Nx | 52 | 5.7 |
| Grade | ||
| GI | 15 | 1.6 |
| GII | 181 | 19.8 |
| GIII | 715 | 78.3 |
| Gx | 1 | |
| Metastasis | ||
| Yes | 170 | 18.6 |
| No | 734 | 80.4 |
| Unknown | 8 | 0.8 |
| Immunohistochemistry and subtype distribution | ||
| ER | ||
| Positive | 494 | 54.0 |
| Negative | 418 | 46.0 |
| ER positive subtype (N = 392) | ||
| ER+/PR+ | 308 | 78.5 |
| ER+/PR− | 77 | 19.6 |
| ER−/PR+ | 7 | 1.7 |
| HER2 positive subtypes (N = 254)a | ||
| ER+ | 109 | 42.9 |
| ER− | 145 | 57.0 |
| Triple negative subtype (N = 266) | ||
| ER/PR/HER2- | 266 | 29.1 |
a4 FISH positive and HER2+ IHC.
ER: oestrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; FISH: fluorescence in situ hybridization.